Patent assignee · US · COMPANY

AstraZeneca Pharmaceuticals LP

38Patents
38Active
38Granted
53Portfolio score

Filing activity: Feb 11, 2005 → May 24, 2018 · 16 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8445647B2 Modified exendins and exendin agonists Human Necessities 48 Active
US8759295B2 Peptide-peptidase inhibitor conjugates and methods of using same Human Necessities 32 Active
US8636689B2 Pen injection device and method of using same Human Necessities 28 Active
US8497240B2 DPP-IV resistant GIP hybrid polypeptides with selectable properties Chemistry; Metallurgy 21 Active
US8603969B2 Pancreatic polypeptide family motifs and polypeptides comprising the same Human Necessities 17 Active
US8329419B2 GLP-1 receptor agonist bioassays Physics 16 Active
US8389473B2 Treatment of cardiac arrhythmias Human Necessities 15 Active
US8481490B2 Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis Human Necessities 15 Active
US8603761B2 GLP-1 receptor agonist bioassay Physics 15 Active
US8551947B2 Treatment of hibernating myocardium with an exendin peptide Human Necessities 15 Active
US8642544B2 N-terminus conformationally constrained GLP-1 receptor agonist compounds Human Necessities 15 Active
US8598120B2 Methods for treatment using amylin family peptides Human Necessities 15 Active
US8426361B2 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same Human Necessities 14 Active
US8906851B2 Method for treating diabetes Chemistry; Metallurgy 11 Active
US8895033B2 Sustained release formulations using non-aqueous carriers Human Necessities 10 Active
US8951962B2 Modified exendins and exendin agonists Human Necessities 4 Active
US8946149B2 Use of exendin and analogs thereof to delay or prevent cardiac remodeling Human Necessities 4 Active
US8394765B2 Methods of treating obesity with two different anti-obesity agents Human Necessities 3 Active
US9217022B2 GLP-1 receptor agonist compounds having stabilized regions Emerging Cross-Sectional Technologies 3 Active
US8501693B2 Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen Chemistry; Metallurgy 3 Active
US9382304B2 Engineered polypeptides having enhanced duration of action with reduced immunogenicity Chemistry; Metallurgy 3 Active
US8598314B2 Peptide-peptidase-inhibitor conjugates and methods of making and using same Human Necessities 2 Active
US8759291B2 Methods of treatment using exendin peptides or GLP-1 peptides Electricity 2 Active
US9593154B2 Engineered polypeptides having enhanced duration of action Chemistry; Metallurgy 2 Active
US9248240B2 Formulation delivery device Human Necessities 1 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.